{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:54:55Z","timestamp":1793699695083,"version":"4.5.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente to IRCCS MultiMedica"],"award-info":[{"award-number":["Ricerca Corrente to IRCCS MultiMedica"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with type 2 diabetes (T2D) are characterized by blunted immune responses, which are affected by glycaemic control. Whether glycaemic control influences the response to COVID-19 vaccines and the incidence of SARS-CoV-2 breakthrough infections is unknown. Here we show that poor glycaemic control, assessed as mean HbA1c in the post-vaccination period, is associated with lower immune responses and an increased incidence of SARS-CoV-2 breakthrough infections in T2D patients vaccinated with mRNA-BNT162b2. We report data from a prospective observational study enroling healthcare and educator workers with T2D receiving the mRNA-BNT162b2 vaccine in Campania (Italy) and followed for one year (5 visits, follow-up 346\u2009\u00b1\u200949 days) after one full vaccination cycle. Considering the 494 subjects completing the study, patients with good glycaemic control (HbA1c one-year mean &lt; 7%) show a higher virus-neutralizing antibody capacity and a better CD4\u2009+\u2009T\/cytokine response, compared with those with poor control (HbA1c one-year mean \u2265 7%). The one-year mean of HbA1c is linearly associated with the incidence of breakthrough infections (Beta\u2009=\u20090.068; 95% confidence interval [CI], 0.032-0.103;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The comparison of patients with poor and good glycaemic control through Cox regression also show an increased risk for patients with poor control (adjusted hazard ratio [HR], 0.261; 95% CI, 0.097-0.700;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.008). Among other factors, only smoking (HR\u2009=\u20090.290, CI 0.146-0.576 for non-smokers;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and sex (HR\u2009=\u20090.105, CI 0.035-0.317 for females;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) are significantly associated with the incidence of breakthrough infections.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-30068-2","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T06:04:48Z","timestamp":1651125888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3960-9270","authenticated-orcid":false,"given":"Raffaele","family":"Marfella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestino","family":"Sardu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2959-2658","authenticated-orcid":false,"given":"Francesco","family":"Prattichizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Scisciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"La Grotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Balestrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Paolisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"30068_CR1","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","volume":"385","author":"M Bergwerk","year":"2021","unstructured":"Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 385, 1474\u20131484 (2021).","journal-title":"N. Engl. J. Med."},{"key":"30068_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01548-7","author":"KB Pouwels","year":"2021","unstructured":"Pouwels, K. B. et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01548-7 (2021).","journal-title":"Nat. Med."},{"key":"30068_CR3","first-page":"00367","volume":"S1198-743X","author":"T Brosh-Nissimov","year":"2021","unstructured":"Brosh-Nissimov, T. et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin. Microbiol. Infect. S1198-743X, 00367\u20130 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"30068_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","volume":"22","author":"M Lipsitch","year":"2022","unstructured":"Lipsitch, M. et al. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat. Rev. Immunol. 22, 57\u201365 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"30068_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41574-021-00608-9","volume":"18","author":"N Stefan","year":"2022","unstructured":"Stefan, N. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Nat. Rev. Endocrinol. 18, 75\u201376 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"30068_CR6","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412\u20131423 (2021).","journal-title":"N. Engl. J. Med."},{"key":"30068_CR7","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S1473-3099(21)00558-2","volume":"21","author":"PV Juthani","year":"2021","unstructured":"Juthani, P. V. et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect. Dis. 21, 1485\u20131486 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"30068_CR8","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S2213-2600(21)00380-5","volume":"9","author":"U Agrawal","year":"2021","unstructured":"Agrawal, U. et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2\u00b757 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir. Med. 9, 1439\u20131449 (2021).","journal-title":"Lancet Respir. Med."},{"key":"30068_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19741-6","volume":"11","author":"H Peckham","year":"2020","unstructured":"Peckham, H. et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat. Commun. 11, 6317 (2020).","journal-title":"Nat. Commun."},{"key":"30068_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.14740\/jocmr4662","volume":"14","author":"R Acharya","year":"2022","unstructured":"Acharya, R. et al. A retrospective cross-sectional study of severe breakthrough SARS-CoV-2 infection in the general population requiring hospitalization within a single health system. J. Clin. Med. Res. 14, 45\u201352 (2022).","journal-title":"J. Clin. Med. Res."},{"key":"30068_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3389\/fendo.2019.00451","volume":"10","author":"P de Candia","year":"2019","unstructured":"de Candia, P. et al. Type 2 diabetes: how much of an autoimmune disease. Front. Endocrinol. 10, 451 (2019).","journal-title":"Front. Endocrinol."},{"key":"30068_CR12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.4161\/hv.28252","volume":"10","author":"Y Egawa","year":"2014","unstructured":"Egawa, Y. et al. Immunogenicity of influenza A(H1N1)pdm09 vaccine in patients with diabetes mellitus: with special reference to age, body mass index, and HbA1c. Hum. Vaccin Immunother. 10, 1187\u20131194 (2014).","journal-title":"Hum. Vaccin Immunother."},{"key":"30068_CR13","doi-asserted-by":"publisher","unstructured":"Prattichizzo F, de Candia P, Nicolucci A, Ceriello A. Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: a sistematic review and meta-analysis. Diabetes Metab. Res. Rev. e3476. https:\/\/doi.org\/10.1002\/dmrr.3476 (2021).","DOI":"10.1002\/dmrr.3476"},{"key":"30068_CR14","doi-asserted-by":"publisher","unstructured":"Marfella R, et al. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study. Diabetes Obes. Metab. https:\/\/doi.org\/10.1111\/dom.14547 (2021).","DOI":"10.1111\/dom.14547"},{"key":"30068_CR15","doi-asserted-by":"publisher","first-page":"101319","DOI":"10.1016\/j.pmedr.2021.101319","volume":"21","author":"MR Alam","year":"2021","unstructured":"Alam, M. R., Kabir, M. R. & Reza, S. Comorbidities might be a risk factor for the incidence of COVID-19: evidence from a web-based survey. Prev. Med. Rep. 21, 101319, https:\/\/doi.org\/10.1016\/j.pmedr.2021.101319 (2021).","journal-title":"Prev. Med. Rep."},{"key":"30068_CR16","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJM199912163412507","volume":"341","author":"N Joshi","year":"1999","unstructured":"Joshi, N., Caputo, G. M., Weitekamp, M. R. & Karchmer, A. W. Infections in patients with diabetes mellitus. N. Engl. J. Med. 341, 1906\u20131912 (1999).","journal-title":"N. Engl. J. Med."},{"key":"30068_CR17","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2018","unstructured":"Fulop, T. et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front. Immunol. 8, 1960 (2018).","journal-title":"Front. Immunol."},{"key":"30068_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1474-9726.2012.00836.x","volume":"11","author":"JS Lefebvre","year":"2012","unstructured":"Lefebvre, J. S. et al. \u201cThe aged microenvironment contributes to the age-related functional defects of CD4 T cells in mice\u201d. Aging Cell 11, 732\u2013740 (2012).","journal-title":"Aging Cell"},{"key":"30068_CR19","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1182\/blood-2002-02-0657","volume":"100","author":"D Voehringer","year":"2002","unstructured":"Voehringer, D., Koschella, M. & Pircher, H. \u201cLack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1)\u201d. Blood 100, 3698\u20133702 (2002).","journal-title":"Blood"},{"key":"30068_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.it.2020.11.002","volume":"42","author":"P de Candia","year":"2021","unstructured":"de Candia, P., Prattichizzo, F., Garavelli, S. & Matarese, G. T cells: warriors of SARS-CoV-2 infection. Trends Immunol. 42, 18\u201330 (2021).","journal-title":"Trends Immunol."},{"key":"30068_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14396-9","volume":"11","author":"EJ M\u00e1rquez","year":"2020","unstructured":"M\u00e1rquez, E. J. et al. Sexual-dimorphism in human immune system aging. Nat. Commun. 11, 751 (2020).","journal-title":"Nat. Commun."},{"key":"30068_CR22","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury D. S, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"30068_CR23","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"30068_CR24","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41591-021-01316-7","volume":"27","author":"M Levine-Tiefenbrun","year":"2021","unstructured":"Levine-Tiefenbrun, M. et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat. Med. 27, 790\u2013792 (2021).","journal-title":"Nat. Med."},{"key":"30068_CR25","doi-asserted-by":"publisher","unstructured":"Petter, E., Mor, O., Zuckerman, N., Oz-Levi, D., Younger, A., Aran, D., Erlich, Y. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. medRxiv https:\/\/doi.org\/10.1101\/2021.02.08.21251329 (2021).","DOI":"10.1101\/2021.02.08.21251329"},{"key":"30068_CR26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.numecd.2020.05.014","volume":"30","author":"A Mantovani","year":"2020","unstructured":"Mantovani, A., Byrne, C. D., Zheng, M. H. & Targher, G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr. Metab. Cardiovasc. Dis. 30, 1236\u20131248 (2020).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"30068_CR27","doi-asserted-by":"publisher","first-page":"108741","DOI":"10.1016\/j.diabres.2021.108741","volume":"174","author":"A Ceriello","year":"2021","unstructured":"Ceriello, A. Diabetes, SARS-CoV-2\/COVID-19 vaccines and glycemic control: call for data. Diabetes Res. Clin. Pract. 174, 108741 (2021).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"30068_CR28","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc20-S002","volume":"43","author":"American Diabetes Association.","year":"2020","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 43, S14\u2013S31 (2020).","journal-title":"Diabetes Care"},{"key":"30068_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s00125-012-2749-0","volume":"56","author":"ML Balestrieri","year":"2013","unstructured":"Balestrieri, M. L. et al. Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation. Diabetologia 56, 162\u2013172 (2013).","journal-title":"Diabetologia"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30068-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:01:30Z","timestamp":1669291290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30068-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["30068"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-30068-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1389539\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2318"}}